NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

The designation covers the use of mesenchymal stem cell (MSC) derived small extracellular vesicles (EVs) loaded with short and modified interfering RNA (siRNA) targeting the phosphatase and tensin homolog (PTEN) protein for acute spinal cord injury, as implemented in the Company’s ExoPTEN drug under development.
[NurExone Biologic, Inc. (Globe Newswire)]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News